BusinessAkari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNHBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAkari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNHBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessProtalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in BrazilBy Nasdaq OMXDec 14, 2016, 12:30 PM UTC
BusinessAkari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered ProteinsBy Nasdaq OMXDec 5, 2016, 12:00 PM UTC
BusinessAkari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXSep 12, 2016, 11:15 AM UTC
